keyword
MENU ▼
Read by QxMD icon Read
search

Lurasidone

keyword
https://www.readbyqxmd.com/read/28098496/real-world-adherence-assessment-of-lurasidone-and-other-oral-atypical-antipsychotics-among-patients-with-schizophrenia-an-administrative-claims-analysis
#1
Krithika Rajagopalan, Sally Wade, Nicole Meyer, Antony Loebel
OBJECTIVE: To compare adherence with lurasidone to other oral atypical antipsychotics among Medicaid- and commercially-insured patients with schizophrenia. RESEARCH DESIGN AND METHODS: Administrative claims of patients with schizophrenia treated with atypical antipsychotics (lurasidone, aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone) from October 2010-September 2011 were identified from MarketScan Commercial and Medicaid Databases, and were classified by the first (index) antipsychotic...
January 18, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28043915/charge-assisted-bond-n-h-mediates-the-gelation-of-amorphous-lurasidone-hydrochloride-during-dissolution
#2
Shuai Qian, Shanshan Wang, Zhen Li, Xiaojie Wang, Di Ma, Shujun Liang, Yuan Gao, Jianjun Zhang, Yuanfeng Wei
Lurasidone hydrochloride (LH), the hydrochloride form of lurasidone with a charge-assisted bond N(+)H, is an atypical antipsychotropic agent for the treatment of schizophrenia. As a BCS class II drug, LH has a low oral bioavailability mainly due to its poor water solubility and low dissolution. In order to improve its solubility, amorphization of LH was performed and characterized. Unexpectedly, the dissolution rate of amorphous LH was much lower than that of crystalline LH. In addition, the amorphous LH powders quickly aggregated when contacting the dissolution media (water, 37°C), and formed a sticky gel adhering on the paddle...
December 30, 2016: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28008349/dosing-patterns-and-medication-adherence-in-bipolar-disorder-patients-treated-with-lurasidone-a-us-retrospective-claims-database-analysis
#3
Martha Sajatovic, Daisy Ng-Mak, Caitlyn T Solem, Fang-Ju Lin, Krithika Rajagopalan, Antony Loebel
BACKGROUND: The aim of this study was to describe dosing patterns and medication adherence among bipolar patients who initiated lurasidone in a real-world setting. METHODS: Adult bipolar patients who initiated lurasidone between 1 November 2010 and 31 December 2012 (index period) with 6-month pre- and post-index continuous enrollment were identified from the IMS RWD Adjudicated Claims US database. Patients were grouped by starting lurasidone daily dose: 20 mg (7...
December 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28004621/augmentation-of-phenelzine-with-aripiprazole-and-quetiapine-in-a-treatment-resistant-patient-with-psychotic-unipolar-depression-case-report-and-literature-review
#4
Jonathan M Meyer, Michael A Cummings, George Proctor
Irreversible monoamine oxidase inhibitor (MAOI) antidepressants have significant efficacy in treatment-resistant unipolar depression, but in some instances patients may not achieve remission. Among the adjunctive and augmentation strategies, certain second-generation antipsychotics (SGAs) have approval for inadequate responders to antidepressant therapy, including aripiprazole, brexpiprazole, and quetiapine, with lurasidone and the olanzapine/fluoxetine combination indicated for bipolar depression. Clinicians may eschew SGA options in part due to the limited literature on SGA-MAOI combinations, with only one published case involving aripiprazole, and none for olanzapine, lurasidone, or brexpiprazole...
December 22, 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27939135/chronic-lurasidone-treatment-normalizes-gabaergic-marker-alterations-in-the-dorsal-hippocampus-of-mice-exposed-to-prenatal-immune-activation
#5
A Luoni, J Richetto, L Longo, M A Riva
Prenatal maternal infection represents a risk factor for the development of psychopathologic conditions later in life. Clinical evidence is also supported by animal models in which the vulnerability to develop a schizophrenic-like phenotype likely originates from inflammatory processes as early as in the womb. Prenatal immune challenge, for example, induces a variety of long-term behavioral alterations in mice, such as deficits in recognition and spatial working memory, perseverative behaviors and social impairments, which are relevant to different symptom clusters of schizophrenia...
December 8, 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27935810/designing-and-analysing-clinical-trials-in-mental-health-an-evidence-synthesis-approach
#6
Simon Wandel, Satrajit Roychoudhury
OBJECTIVE: When planning a clinical study, evidence on the treatment effect is often available from previous studies. However, this evidence is mostly ignored for the analysis of the new study. This is unfortunate, since using it could lead to a smaller study without compromising power. We describe a design that addresses this issue. METHODS: We use a Bayesian meta-analytic model to incorporate the available evidence in the analysis of the new study. The shrinkage estimate for the new study integrates the evidence from the other studies...
November 2016: Evidence-based Mental Health
https://www.readbyqxmd.com/read/27833522/histamine-h3-receptors-and-its-antagonism-as-a-novel-mechanism-for-antipsychotic-effect-a-current-preclinical-clinical-perspective
#7
REVIEW
Danish Mahmood
Histamine H3 receptors are present as autoreceptors on histaminergic neurons and as heteroreceptors on nonhistaminergic neurones. They control the release and synthesis of histamine and several other key neurotransmitters in the brain. H3 antagonism may be a novel approach to develop a new class of antipsychotic medications given the gathering evidence reporting therapeutic efficacy in several central nervous system disorders. Several medications such as cariprazine, lurasidone, LY214002, bexarotene, rasagiline, raloxifene, BL-1020 and ITI-070 are being developed to treat the negative symptoms and cognitive impairments of schizophrenia...
October 2016: International Journal of Health Sciences
https://www.readbyqxmd.com/read/27722855/pharmacokinetics-and-pharmacodynamics-of-lurasidone-hydrochloride-a-second-generation-antipsychotic-a-systematic-review-of-the-published-literature
#8
William M Greenberg, Leslie Citrome
Lurasidone hydrochloride, a benzisothiazol derivative, is a second-generation (atypical) antipsychotic agent that has received regulatory approval for the treatment of schizophrenia in the US, Canada, the EU, Switzerland, and Australia, and also for bipolar depression in the US and Canada. In addition to its principal antagonist activity at dopamine D2 and serotonin 5-HT2A receptors, lurasidone has distinctive 5-HT7 antagonistic activity, and displays partial agonism at 5-HT1A receptors, as well as modest antagonism at noradrenergic α2A and α2C receptors...
October 8, 2016: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/27629159/treatment-recommendations-for-dsm-5-defined-mixed-features
#9
Joshua D Rosenblat, Roger S McIntyre
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) mixed features specifier provides a less restrictive definition of mixed mood states, compared to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), including mood episodes that manifest with subthreshold symptoms of the opposite mood state. A limited number of studies have assessed the efficacy of treatments specifically for DSM-5-defined mixed features in mood disorders. As such, there is currently an inadequate amount of data to appropriately inform evidence-based treatment guidelines of DSM-5 defined mixed features...
September 15, 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27563237/schizophrenia-relapse-patient-considerations-and-potential-role-of-lurasidone
#10
REVIEW
Leslie Citrome
When treating persons with schizophrenia, delaying time to relapse is a main goal. Antipsychotic medication has been the primary treatment approach, and there are a variety of different choices available. Lurasidone is a second-generation (atypical) antipsychotic agent that is approved for the treatment of schizophrenia and bipolar depression. Three long-term studies of lurasidone have examined time to relapse in persons with schizophrenia, including a classic placebo-controlled randomized withdrawal study and two 12-month active comparator studies (vs risperidone and vs quetiapine extended-release)...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27529375/efficacy-of-lurasidone-in-adults-aged-55-years-and-older-with-bipolar-depression-post-hoc-analysis-of-2-double-blind-placebo-controlled-studies
#11
Martha Sajatovic, Brent P Forester, Joyce Tsai, Hans Kroger, Andrei Pikalov, Josephine Cucchiaro, Antony Loebel
OBJECTIVE: The aim of this post hoc analysis was to evaluate the efficacy of lurasidone in patients aged 55 years and older with bipolar depression. METHODS: A post hoc analysis was performed on the older adult subgroup (n = 142) of outpatients meeting DSM-IV-TR criteria for bipolar I depression in 2 placebo-controlled, 6-week, randomized, double-blind studies conducted from 2009-2012: a monotherapy study comparing fixed flexible-dose ranges of lurasidone 20-60 mg/d or 80-120 mg/d with placebo and an adjunctive therapy study comparing flexible doses of lurasidone 20-120 mg/d with placebo adjunctive to either lithium or valproate...
August 16, 2016: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/27518477/an-open-trial-of-lurasidone-as-an-acute-and-maintenance-adjunctive-treatment-for-outpatients-with-treatment-resistant-bipolar-disorder-response-to-letter-to-the-editors
#12
Charles B Schaffer, Linda C Schaffer, Thomas E Nordahl, Nicole M Stark, Caroline E Gohring
No abstract text is available yet for this article.
October 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27518474/comment-on-an-open-trial-of-lurasidone-as-an-acute-and-maintenance-adjunctive-treatment-for-outpatients-with-treatment-resistant-bipolar-disorder
#13
Ian Ross McGrane, Matej Stuhec
No abstract text is available yet for this article.
October 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27454547/lurasidone-dose-escalation-in-early-nonresponding-patients-with-schizophrenia-a-randomized-placebo-controlled-study
#14
Antony Loebel, Robert Silva, Robert Goldman, Kei Watabe, Josephine Cucchiaro, Leslie Citrome, John M Kane
OBJECTIVE: To assess the effect of dose increase in adult patients with schizophrenia who demonstrate inadequate initial response to standard-dose lurasidone and to evaluate the efficacy of low-dose lurasidone in adult patients with schizophrenia. METHODS: In this randomized, double-blind, placebo-controlled study conducted between May 2013 and June 2014, hospitalized patients with acute schizophrenia (DSM-IV-TR criteria) were randomly assigned to double-blind treatment with lurasidone 20 mg/d (n = 101), lurasidone 80 mg/d (n = 199), or placebo (n = 112)...
December 2016: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/27372312/antipsychotic-drug-induced-somnolence-incidence-mechanisms-and-management
#15
REVIEW
Fang Fang, Hongwei Sun, Zuowei Wang, Ming Ren, Joseph R Calabrese, Keming Gao
Somnolence is a common side effect of antipsychotics. To assess the incidence of this side effect, we performed a MEDLINE search for randomized, double-blinded, placebo- or active-controlled studies of adult patients treated with antipsychotics for schizophrenia, mania, bipolar depression, or bipolar disorder. We extracted rates of somnolence from original publications and pooled them based on the dose of each antipsychotic in the same psychiatric condition, then estimated the absolute risk increase (ARI) and the number needed to harm (NNH) of an antipsychotic relative to placebo or an active comparator in the same psychiatric condition...
September 2016: CNS Drugs
https://www.readbyqxmd.com/read/27347638/an-update-of-safety-of-clinically-used-atypical-antipsychotics
#16
L Orsolini, C Tomasetti, A Valchera, R Vecchiotti, I Matarazzo, F Vellante, F Iasevoli, E F Buonaguro, M Fornaro, A L C Fiengo, G Martinotti, M Mazza, G Perna, A Carano, A De Bartolomeis, M Di Giannantonio, D De Berardis
INTRODUCTION: The atypical antipsychotic (APs) drugs have become the most widely used agents to treat a variety of psychoses because of their superiority with regard to safety and tolerability profile compared to conventional/'typical' APs. AREAS COVERED: We aimed at providing a synthesis of most current evidence about the safety and tolerability profile of the most clinically used atypical APs so far marketed. Qualitative synthesis followed an electronic search made inquiring of the following databases: MEDLINE, Embase, PsycINFO and the Cochrane Library from inception until January 2016, combining free terms and MESH headings for the topics of psychiatric disorders and all atypical APs as following: ((safety OR adverse events OR side effects) AND (aripiprazole OR asenapine OR quetiapine OR olanzapine OR risperidone OR paliperidone OR ziprasidone OR lurasidone OR clozapine OR amisulpride OR iloperidone))...
October 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27328703/a-case-of-a-probable-drug-interaction-between-lurasidone-and-atazanavir-based-antiretroviral-therapy
#17
Mark Naccarato, Elise Hall, Alan Wai, Mario Ostrowski, Adriana Carvalhal
The cytochrome P450 isoform that is primarily involved in the metabolism of the antipsychotic lurasidone is CYP3A4. Drugs that inhibit or induce this enzyme would then be expected to increase or decrease serum concentrations of lurasidone, respectively. Atazanavir, an HIV-1 protease inhibitor, has demonstrated to be an inhibitor of CYP3A4 and would be expected to increase the exposure of any drug metabolized by this enzyme. We report a case of an atazanavir-precipitated drug-drug interaction that led to elevated serum concentrations of lurasidone and associated clinical symptoms of drug toxicity...
2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27321864/the-effects-of-second-generation-antipsychotic-drugs-on-sleep-variables-in-healthy-subjects-and-patients-with-schizophrenia
#18
Jaime M Monti, Pablo Torterolo, Seithikurippu R Pandi Perumal
Insomnia is a common feature in schizophrenia, and is characterized by an increase of sleep latency (SL), as well as reductions in total sleep time (TST) and sleep efficiency (SE). Regarding sleep architecture, non-rapid-eye-movement (NREM) sleep, slow wave sleep (SWS) and rapid-eye-movement (REM) sleep latency are decreased, whereas REM sleep tends to remain unchanged. According to polysomnographic studies, clozapine, olanzapine, quetiapine and ziprasidone administration increased TST and/or SE in healthy subjects...
May 15, 2016: Sleep Medicine Reviews
https://www.readbyqxmd.com/read/27274384/pharmacotherapy-of-acute-bipolar-depression-in-adults-an-evidence-based-approach
#19
REVIEW
Ather Muneer
In the majority of cases of bipolar disorder, manic episodes are usually brief and typically responsive to currently available psychopharmacological agents. In contrast, depressive manifestations are more prevalent and persistent, and can present as major depressive/mixed episodes or residual interepisode symptoms. The depressive phase is often associated with other neuropsychiatric conditions, such as anxiety spectrum disorders, substance use disorders, stressor-related disorders, and eating disorders. It is viewed as a systemic disease with associated ailments such as metabolic syndrome, diabetes mellitus, and cardiovascular disease...
May 2016: Korean Journal of Family Medicine
https://www.readbyqxmd.com/read/27245981/long-term-health-related-quality-of-life-improvements-among-patients-treated-with-lurasidone-results-from-the-open-label-extension-of-a-switch-trial-in-schizophrenia
#20
George Awad, Daisy Ng-Mak, Krithika Rajagopalan, Jay Hsu, Andrei Pikalov, Antony Loebel
BACKGROUND: Long-term improvement of health-related quality of life (HRQoL) in schizophrenia may improve adherence and reduce relapse and rehospitalization. This analysis examines long-term changes in HRQoL among patients with schizophrenia switched to lurasidone from other antipsychotics. METHODS: Patients who completed an open-label 6-week switch study continued on lurasidone for an additional 24-weeks. HRQoL was measured using the self-reported Personal Evaluation of Transitions in Treatment (PETiT) scale and Short-Form 12 (SF-12) questionnaire...
June 1, 2016: BMC Psychiatry
keyword
keyword
27111
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"